SCHEMBL31268855

SCHEMBL31268855

CC1(Oc2ncnc3c2nc(-c2ccc(C(=O)O)cc2Cl)n3Cc2cccc(Cl)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.38
▸ PLA2G2A P14555 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ PIK3CD O00329 2/20 0.36
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ CCR2 P41597 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PTGER4 P35408 1/20 0.36
▸ PTGDR Q13258 1/20 0.36
▸ PDE1B Q01064 2/20 0.35
▸ P2RY14 Q15391 1/20 0.35
▸ NR1I2 O75469 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35
▸ RXRA P19793 1/20 0.35
▸ RXRB P28702 1/20 0.35
▸ RXRG P48443 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ NR4A2 P43354 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ SCN1A P35498 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983906 0.94 PIK3CD (0.39) CNR1PIK3CDNR1I2HSD11B1
SCHEMBL30983850 0.89 CNR1 (0.40) CNR1PIK3CDMAPTPDE1BHTR6
SCHEMBL31321972 0.88 PIK3CD (0.38) CNR1PIK3CD
SCHEMBL31269133 0.88 PLA2G2A (0.38) CNR1PLA2G2APIK3CDPTGDR2MAPT
SCHEMBL30983451 0.87 PLA2G2A (0.38) CNR1PLA2G2APIK3CDPTGDR2SCN1A
SCHEMBL30984005 0.87 CFTR (0.40) CNR1PIK3CD
SCHEMBL31269035 0.87 CNR1 (0.36) CNR1PLA2G2APIK3CDPTGDR2HTR6
SCHEMBL30984067 0.87 CNR1 (0.40) CNR1PIK3CDPDE1BHTR6SCN1A
SCHEMBL30983480 0.86 F2 (0.39) CNR1PIK3CD
SCHEMBL31321968 0.86 MAPK14 (0.40) CNR1PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback